|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/18/19 Aclaris Therapeutics, Inc. 10-K 12/31/18 97:13M Toppan Merrill Bridge/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.69M
2: EX-10.11 Material Contract HTML 89K
3: EX-10.12 Material Contract HTML 76K
4: EX-10.15 Material Contract HTML 32K
5: EX-10.27 Material Contract HTML 38K
6: EX-10.31 Material Contract HTML 443K
7: EX-21.1 Subsidiaries List HTML 28K
8: EX-23.1 Consent of Experts or Counsel HTML 27K
9: EX-31.1 Certification -- §302 - SOA'02 HTML 32K
10: EX-31.2 Certification -- §302 - SOA'02 HTML 31K
11: EX-32.1 Certification -- §906 - SOA'02 HTML 32K
18: R1 Document and Entity Information HTML 61K
19: R2 Consolidated Balance Sheets HTML 110K
20: R3 Consolidated Balance Sheets (Parenthetical) HTML 45K
21: R4 Consolidated Statements of Operations and HTML 86K
Comprehensive Loss
22: R5 Consolidated Statements of Operations and HTML 29K
Comprehensive Loss (Parenthetical)
23: R6 Consolidated Statements of Stockholders' Equity HTML 95K
24: R7 Consolidated Statements of Stockholders' Equity HTML 32K
(Parenthetical)
25: R8 Consolidated Statements of Cash Flows HTML 128K
26: R9 Organization and Nature of Business HTML 34K
27: R10 Summary of Significant Accounting Policies HTML 129K
28: R11 Acquisitions HTML 108K
29: R12 Fair Value of Financial Assets and Liabilities HTML 220K
30: R13 Property and Equipment, Net HTML 59K
31: R14 Intangible Assets HTML 84K
32: R15 Accrued Expenses HTML 57K
33: R16 Debt HTML 34K
34: R17 Stockholders' Equity HTML 42K
35: R18 Stock-Based Awards HTML 219K
36: R19 Net Loss per Share HTML 71K
37: R20 Commitments and Contingencies HTML 51K
38: R21 Income Taxes HTML 187K
39: R22 Related Party Transactions HTML 92K
40: R23 Agreements Related to Intellectual Property HTML 51K
41: R24 Retirement Savings Plan HTML 31K
42: R25 Segment Information HTML 150K
43: R26 Quarterly Financial Information (Unaudited) HTML 98K
44: R27 Summary of Significant Accounting Policies HTML 197K
(Policies)
45: R28 Summary of Significant Accounting Policies HTML 46K
(Tables)
46: R29 Acquisitions (Tables) HTML 105K
47: R30 Fair Value of Financial Assets and Liabilities HTML 217K
(Tables)
48: R31 Property and Equipment, Net (Tables) HTML 58K
49: R32 Intangible Assets (Tables) HTML 85K
50: R33 Accrued Expenses (Tables) HTML 56K
51: R34 Stock-Based Awards (Tables) HTML 215K
52: R35 Net Loss per Share (Tables) HTML 72K
53: R36 Commitments and Contingencies (Tables) HTML 41K
54: R37 Income Taxes (Tables) HTML 180K
55: R38 Related Party Transactions (Tables) HTML 85K
56: R39 Segment Information (Tables) HTML 147K
57: R40 Quarterly Financial Information (Unaudited) HTML 97K
(Tables)
58: R41 Organization and Nature of Business (Details) HTML 34K
59: R42 Summary of Significant Accounting Policies HTML 43K
(Details)
60: R43 Summary of Significant Accounting Policies - HTML 40K
Product Sales (Details)
61: R44 Summary of Significant Accounting Policies - HTML 51K
Deferred Costs (Details)
62: R45 Summary of Significant Accounting Policies - Risk HTML 36K
(Details)
63: R46 Summary of Significant Accounting Policies - HTML 45K
Recent Pronouncements (Details)
64: R47 Summary of Significant Accounting Policies - HTML 27K
Segments (Details)
65: R48 Acquisitions - Amount Paid for Assets Acquired HTML 38K
(Details)
66: R49 Acquisitions - Summary of Fair Value Assets HTML 38K
Acquired (Details)
67: R50 Acquisitions - Summary of Fair Value Consideration HTML 51K
(Details)
68: R51 Acquisitions - Fair Value of Assets Acquired and HTML 63K
Liabilities Assumed (Details)
69: R52 Acquisitions - Supplemental Pro Forma Financial HTML 41K
Information (Details)
70: R53 Fair Value of Financial Assets and Liabilities HTML 70K
(Details)
71: R54 Fair Value of Financial Assets and Liabilities - HTML 44K
By type (Details)
72: R55 Property and Equipment, Net (Details) HTML 52K
73: R56 Intangible Assets (Details) HTML 49K
74: R57 Intangible Assets - Future Amortization Expenses HTML 49K
(Details)
75: R58 Accrued Expenses (Details) HTML 51K
76: R59 Debt (Details) HTML 59K
77: R60 Stockholders' Equity (Details) HTML 40K
78: R61 Stockholders' Equity - Other Offerings (Details) HTML 81K
79: R62 Stock-Based Awards (Details) HTML 72K
80: R63 Stock-Based Awards - Option Activity (Details) HTML 88K
81: R64 Stock-Based Awards - RSUs (Details) HTML 53K
82: R65 Stock-Based Awards - Compensation (Details) HTML 51K
83: R66 Net Loss per Share (Details) HTML 41K
84: R67 Net Loss per Share - Anti-dilution (Details) HTML 35K
85: R68 Commitments and Contingencies (Details) HTML 58K
86: R69 Income Taxes - Tax Cuts and Jobs Act (Details) HTML 40K
87: R70 Income Taxes - Rate Reconciliation (Details) HTML 73K
88: R71 Income Taxes - Deferred Assets and Liabilities, HTML 92K
CFDs (Details)
89: R72 Income Taxes - Valuation Allowance and HTML 54K
Unrecognized Tax Benefits (Details)
90: R73 Related Party Transactions (Details) HTML 57K
91: R74 Agreements Related to Intellectual Property HTML 92K
(Details)
92: R75 Retirement Savings Plan (Details) HTML 32K
93: R76 Segment Information (Details) HTML 66K
94: R77 Quarterly Financial Information (Unaudited) HTML 48K
(Details)
96: XML IDEA XML File -- Filing Summary XML 168K
95: EXCEL IDEA Workbook of Financial Reports XLSX 112K
12: EX-101.INS XBRL Instance -- acrs-20181231 XML 3.32M
14: EX-101.CAL XBRL Calculations -- acrs-20181231_cal XML 226K
15: EX-101.DEF XBRL Definitions -- acrs-20181231_def XML 688K
16: EX-101.LAB XBRL Labels -- acrs-20181231_lab XML 1.72M
17: EX-101.PRE XBRL Presentations -- acrs-20181231_pre XML 1.13M
13: EX-101.SCH XBRL Schema -- acrs-20181231 XSD 204K
97: ZIP XBRL Zipped Folder -- 0001558370-19-002211-xbrl Zip 235K
| acrs EX1027 |
Exhibit 10.27
FIRST AMENDMENT TO SUBLEASE
This First Amendment to Sublease (this “Amendment”) dated as of this 13th day of December, 2017 by and between Aclaris Therapeutics, Inc., a Delaware corporation, with offices located at 101 Lindenwood Drive, Suite 400, Malvern, Pennsylvania 19355 (“Subtenant”), and Auxilium Pharmaceuticals, LLC, a Delaware limited liability company, with offices located at 1400 Atwater Drive, Malvern, PA 19355 (“Sublandlord”).
W I T N E S S E T H:
WHEREAS, Sublandlord and Subtenant entered into that certain Sublease dated as of November 2, 2017 (the “Sublease”), pursuant to which Sublandlord subleased to Subtenant that certain Sublease Premises consisting of 33,019 square feet of space in the aggregate located at 640 Lee Road, Wayne, PA, comprised of the entire second floor of the Master Lease Premises and a portion of the first floor, as more fully described in the Lease;
WHEREAS, Sublandlord and Subtenant have agreed to modify the Sublease to permit Subtenant to make certain alterations to the Sublease Premises, subject to the terms and conditions hereof.
NOW, THEREFORE, for and in consideration of the aforesaid recitals and the covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties hereto, Sublandlord and Subtenant hereby agree as follows:
1. Capitalized Terms. Capitalized terms used herein, but not defined herein, shall have the meanings ascribed to such terms in the Sublease.
2. Alterations to Sublease Premises. Subtenant shall be permitted to make those certain alterations to the Subleased Premises as shown on and in accordance with the plans attached hereto as Exhibit A, provided that prior to the expiration of the Term, Subtenant, at its sole cost and expense, shall restore the Sublease Premises to its original condition that existed immediately prior to Subtenant’s use of and alterations to the Sublease Premises. The Master Landlord has consented to such alterations to the Sublease Premises, subject to the restoration condition stated herein. Subtenant shall indemnify, defend and hold Sublandlord harmless from and against any and all losses, costs, damages, expenses and liability, including, but not limited to, reasonable attorneys’ fees, which Sublandlord may incur in connection with Subtenant’s alterations to and subsequent restoration of the Sublease Premises, including, without limitation, Subtenant’s failure to restore the Sublease Premises to the satisfaction of Master Landlord before the expiration of the Term.
3. Miscellaneous. Except as hereinabove provided, all other terms and conditions of the Sublease shall remain unchanged and in full force and effect. This Amendment may be executed in counterparts, each of which shall be deemed an original, and all of which together shall constitute one Amendment. This Amendment together with the Sublease, is the complete understanding between the parties and supersedes all other prior agreements and representations concerning its subject matter.
[Signatures on following page]
1
IN WITNESS WHEREOF, this Amendment has been duly executed by Sublandlord and Subtenant as of the day and year first herein above written.
|
|
SUBLANDLORD: |
||
|
|
|
||
|
|
|
||
|
|
AUXILIUM PHARMACEUTICALS, LLC |
||
|
|
a Delaware limited liability company |
||
|
|
|
||
|
|
|
||
|
|
By: |
||
|
|
|
Name: |
|
|
|
|
Title: |
Executive Vice President, Human Resources |
|
|
|
||
|
|
SUBTENANT: |
||
|
|
|
||
|
|
|
||
|
|
ACLARIS THERAPEUTICS, INC. |
||
|
|
a Delaware corporation |
||
|
|
|
||
|
|
|
||
|
|
By: |
/s/ Neal Walker |
|
|
|
|
Name: |
|
|
|
|
Title: |
President & CEO |
EXHIBIT A
ALTERATION PLANS
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/18/19 | 8-K | ||
| For Period end: | 12/31/18 | |||
| 11/2/17 | 8-K | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/07/24 Aclaris Therapeutics, Inc. S-8 5/07/24 4:78K Toppan Merrill/FA 2/27/24 Aclaris Therapeutics, Inc. 10-K 12/31/23 91:11M Toppan Merrill Bridge/FA 5/08/23 Aclaris Therapeutics, Inc. S-8 5/08/23 4:78K Toppan Merrill/FA 2/23/23 Aclaris Therapeutics, Inc. 10-K 12/31/22 88:11M Toppan Merrill Bridge/FA 5/10/22 Aclaris Therapeutics, Inc. S-8 5/10/22 4:79K Toppan Merrill/FA 2/24/22 Aclaris Therapeutics, Inc. 10-K 12/31/21 98:12M Toppan Merrill Bridge/FA 5/07/21 Aclaris Therapeutics, Inc. S-8 5/07/21 3:83K Toppan Merrill/FA 2/25/21 Aclaris Therapeutics, Inc. 10-K 12/31/20 104:12M Toppan Merrill Bridge/FA |